IIVS, Non Animal Testing, Alternative Test Methods, In Vitro Toxicology | Assays Sensitization
84
archive,tax-assay,term-sensitization,term-84,ajax_fade,page_not_loaded,,qode_grid_1300,footer_responsive_adv,hide_top_bar_on_mobile_header,qode-content-sidebar-responsive,qode-child-theme-ver-,qode-theme-ver-11.0,qode-theme-bridge,wpb-js-composer js-comp-ver-4.11.2.1,vc_responsive

Archive

IIVS and BASF Collaborate to Distribute Test Method to Replace Animal Testing in China

January 9, 2018
GAITHERSBURG, MD – January 9, 2018 – The Institute for In Vitro Sciences, Inc. (IIVS) today announced a collaboration with BASF to import a non-animal, cell based, safety test into China. The LuSens test, developed by BASF, is an in vitro test to detect the sensitization potential of chemicals to human skin. The test was developed to be license free and shared with the scientific community at-large. It has recently been incorporated into the Organization for Economic Co-operation and Development...

Webinar: How GLPs Enhance the Quality of Regulated and Non-Regulated Toxicology

October 18, 2016
This one-hour webinar, led by IIVS Director of Quality and Compliance, introduces some of the concepts of Good Laboratory Practices (GLPs) designed to promote study and data integrity within an in vitro toxicology framework. Applying these concepts within your own laboratory should aid in production of robust, repeatable studies. View Slides...

Integrated Testing Strategies for Skin Sensitization

August 24, 2016
Determination of skin sensitization potential is a critical endpoint in the safety assessment of raw materials, chemicals, mixtures and formulations.  Although the Guinea Pig Maximization Test (GPMT) and Local Lymph node assay (LLNA) have historically been used to address this adverse effect, in vitro assays have been developed and validated in order to replace these resource-intensive animal tests. Skin sensitization is the result of a series of biochemical "Key Events" (KEs) that involve covalent binding of (generally electrophilic) compounds to cellular...

LuSens (OECD 442D)

August 24, 2016
Similar to the KeratinoSens assay (OECD 442D), also offered by IIVS, LuSens addresses the cellular event of Keratinocyte activation, the second key event that triggers the induction of skin sensitization.  It is a luciferase-assay bioassay performed in a human keratinocyte cell line.  The approach is based on evaluating the upregulation of a gene involved in the induction of the sensitization response. IIVS participated in an inter-laboratory study led by BASF to assess the transferability, reproducibility, and accuracy of the method.  The...

Human Cell Line Activation Test (h-CLAT, OECD 442E)

August 24, 2016
The human Cell Line Activation Test (h-CLAT) is a cell-based assay that identifies skin sensitizers by examining changes in the expression of cell surface markers (CD54 and CD86) implicated in dendritic cell activation, the third key event of the skin sensitization AOP.  Following exposure of the THP-1 human monocyte cell line to the test substance, expression levels of CD54 and CD86 are quantified by flow cytometry and compared to controls. The method has been reviewed by the European Union Reference Laboratory...

Direct Peptide Reactivity Activation Assay (DPRA, OECD 442C)

August 24, 2016
The DPRA  (OECD 442C) is an in chemico assay that  models the first key event in the skin sensitization Adverse Outcome Pathway (AOP) - skin, protein reactivity. Compounds implicated in causing Allergic Contact Dermatitis (ACD) are generally electrophilic in nature. This assay identifies dermal sensitizers based on their reactivity with synthetic peptides containing the nucleophilic amino acid residues lysine and cysteine. Using LC/UV, conjugation of the test material with the peptides can be analyzed. Trained by the developers of this assay (Procter &...

KeratinoSens (OECD 442D)

August 24, 2016
The KeratinoSensTM assay is a cell-based reporter gene assay that models the second key event in the Adverse Outcome Pathway for Dermal Sensitization, namely keratinocyte activation.  This approach measures the induction of luciferase under the control of the antioxidant response element (ARE) derived from the human AKR1C2 gene, and can be used in a Weight of Evidence approach as an alternative to animal testing methods for the purpose of hazard identification. IIVS has participated in validation studies led by the assay developer...

Next Generation Tobacco Products

August 24, 2016
IIVS has a long-standing history of working with various industries to help establish or utilize in vitro models for the prediction of risk and the assessment of products under development. With the Food and Drug Administration extending its authority to all tobacco products (including e-cigarettes, cigars, and hookah) the tobacco industry is faced with the task of assessing product safety for product development and regulatory submission. Further, the manufacture of tobacco products may entail risk to workers that come in...

Fragrance & Flavors

August 24, 2016
Exposure to fragrance chemicals is most commonly by direct skin contact. Allergic contact dermatitis (ACD) to fragrance ingredients is most often caused by cosmetic products, such as perfumes, deodorants, and aftershave products. Cosmetic fragrance ingredients should be assessed for exposure damage including skin sensitization (ACD), phototoxicity, skin irritation (irritant contact dermatitis), and respiratory irritation and sensitization. At IIVS, we have pre-clinical testing programs to address each of these endpoints to ensure the safety of fragrance ingredients.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...

Cosmetics & Personal Care

August 24, 2016
European legislation and US research activities towards ‘21st century toxicology’ are setting the standards for animal-free toxicological assessments and the cosmetics industry has been the first to feel the effects. As per EU Regulation 1223/2009, animal testing of cosmetic ingredients and finished products is currently banned in the EU, as is the marketing of finished cosmetic products and the ingredients contained therein which were tested on animals for cosmetic safety assessment purposes. These bans hold irrespective of the availability of validated...